Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy
Launched by DAN LIU · Jan 17, 2025
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with sleep apnea hypopnea syndrome were included
- Exclusion Criteria:
- • Patients were excluded if they had nasal obstruction, significantly deviated nasal septum, nasal turbinate hypertrophy, or nasal polyps. Patients with uncontrolled heart failure, renal insufficiency, diabetes, or hyperthyroidism were also excluded. Patients were also excluded if taking medications that could affect upper airway muscle function, such as ben- zodiazepines and muscle relaxants.
About Dan Liu
Dan Liu is a distinguished clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on improving patient outcomes, Dan Liu collaborates with leading healthcare professionals and research institutions to design and implement rigorous clinical trials across various therapeutic areas. Committed to ethical practices and regulatory compliance, the organization prioritizes patient safety and data integrity while striving to bring groundbreaking treatments to market. Through its expertise in trial management and a patient-centric approach, Dan Liu aims to contribute significantly to the future of healthcare and therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported